Drug
Biological Muc1 Peptide Specific Immunotherapy
Biological Muc1 Peptide Specific Immunotherapy: highest development phase Phase 1, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Biological: MUC1 peptide specific immunotherapy NCT01731587 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) Stage III |
Latest
No recent events.
Follow Biological Muc1 Peptide Specific Immunotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.